Abstract
Dual binding site acetylcholinesterase inhibitors have recently emerged as a new class of anti-Alzheimer agents with potential to positively modify the course of the disease. These compounds exhibit a multifunctional pharmacological profile arising from interaction with several biological targets involved upstream and downstream in the neurodegenerative cascade of Alzheimers disease (AD). The primary target of these compounds is the enzyme acetylcholinesterase (AChE). Interaction of dual binding site AChE inhibitors with AChE results in a potent inhibitory activity of AChE and AChE-induced β-amyloid peptide (Aβ) aggregation. Some dual binding site AChE inhibitors take on added value a significant ability to additionally inhibit the enzymes butyrylcholinesterase and BACE-1, involved in the co-regulation of the hydrolysis of the neurotransmitter acetylcholine and in Aβ formation, respectively. The structural determinants which mediate the interaction of dual binding site AChE inhibitors with these three important enzymes for AD treatment are herein reviewed.
Keywords: Acetylcholinesterase, butyrylcholinesterase, BACE-1, drug-target interactions, structure-based drug design, Anti-Alzheimer agents, Alzheimer's disease, AChE inhibitors, b-amyloid peptide, Dementia, Endoproteinases, Ab vaccine, Ramiprosate, AN1792, Bapineuzumab, CTS-21166, LY450139, MK 0752, E2012, Tacrine, Donepezil, Rivastigmine, Galantamine, Protofibrils, Amylospheroids, Torpedo californica, Thioflavin T fluorescence, Anti-TZ2PA6, Physostigmine analogue, BChE inhibitors, Memoquin
Current Pharmaceutical Design
Title: Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Volume: 16 Issue: 25
Author(s): Carles Galdeano, Elisabet Viayna, Pau Arroyo, Axel Bidon-Chanal, J. Ramon Blas, Diego Munoz-Torrero and F. Javier Luque
Affiliation:
Keywords: Acetylcholinesterase, butyrylcholinesterase, BACE-1, drug-target interactions, structure-based drug design, Anti-Alzheimer agents, Alzheimer's disease, AChE inhibitors, b-amyloid peptide, Dementia, Endoproteinases, Ab vaccine, Ramiprosate, AN1792, Bapineuzumab, CTS-21166, LY450139, MK 0752, E2012, Tacrine, Donepezil, Rivastigmine, Galantamine, Protofibrils, Amylospheroids, Torpedo californica, Thioflavin T fluorescence, Anti-TZ2PA6, Physostigmine analogue, BChE inhibitors, Memoquin
Abstract: Dual binding site acetylcholinesterase inhibitors have recently emerged as a new class of anti-Alzheimer agents with potential to positively modify the course of the disease. These compounds exhibit a multifunctional pharmacological profile arising from interaction with several biological targets involved upstream and downstream in the neurodegenerative cascade of Alzheimers disease (AD). The primary target of these compounds is the enzyme acetylcholinesterase (AChE). Interaction of dual binding site AChE inhibitors with AChE results in a potent inhibitory activity of AChE and AChE-induced β-amyloid peptide (Aβ) aggregation. Some dual binding site AChE inhibitors take on added value a significant ability to additionally inhibit the enzymes butyrylcholinesterase and BACE-1, involved in the co-regulation of the hydrolysis of the neurotransmitter acetylcholine and in Aβ formation, respectively. The structural determinants which mediate the interaction of dual binding site AChE inhibitors with these three important enzymes for AD treatment are herein reviewed.
Export Options
About this article
Cite this article as:
Galdeano Carles, Viayna Elisabet, Arroyo Pau, Bidon-Chanal Axel, Ramon Blas J., Munoz-Torrero Diego and Javier Luque F., Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents, Current Pharmaceutical Design 2010; 16 (25) . https://dx.doi.org/10.2174/138161210793176536
DOI https://dx.doi.org/10.2174/138161210793176536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Artemisia Species as Potential Weapon Against Agents and Agricultural Pests
Current Biotechnology Ezetimibe and Its Inhibitory Effects on Intestinal Cholesterol Absorption
Vascular Disease Prevention (Discontinued) Biodegradable Biomaterials
Recent Patents on Biomedical Engineering (Discontinued) Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
Endocrine, Metabolic & Immune Disorders - Drug Targets Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design GPU-Based Acceleration of ECG Characterization Using High-Order Hermite Polynomials
Current Bioinformatics Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Can Edible Insects Complement Conventional Livestock? The Desirability of Insect Nutrition for Food Security of a World Heritage Site and Biosphere Reserve
Current Nutrition & Food Science Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology Long-Term Multimodal Therapy (Verapamil Associated with Propolis, Blueberry, Vitamin E and Local Diclofenac) on Patients with Peyronie's Disease (Chronic Inflammation of the Tunica Albuginea). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research